Cell X and Colonyze Platform for Cell Sourcing and Process Controls
Poster Feb 15, 2017
Venkata Mantripragada, Viviane Luangphakdy, George Muschler, Travis Schneider, and Brian Handerhan
Cells are the core resource for biological products & biomanufacturing. No new tissue is formed without cells. Cell populations from different donors/tissues vary highly in concentration, prevalence, & biological potential. The challenge: managing this variation in design, fabrication, & quality control of all cell therapies.
Innovators of new therapies must have control over cell sources, quality, & biological attributes of cells entering/leaving the processing chain.
The cell sourcing and product quality mantra:
- Know what you have.
- Pick what you want.
- Show what you’ve done.
- Know how to do it again.
Quantitative metrics must be used to define critical quality attributes (CQAs) of cell sources and cell products.
P450 Induction in Cryopreserved Hepatocytes from PXR and CAR Nuclear Receptor Knock-out RatsPoster
The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that regulate the expression of phase I (cytochrome P450s), phase II metabolizing enzymes and transporter genes in response to xenobiotics, including prescription drugs.READ MORE
Mass Spectrometry: From Imaging to Metabolic NetworksPoster
We show that network analysis of co-localized ions from mass spectrometry imaging data provides a detailed chemo-spatial insight into the metabolic heterogeneity of tumors. Furthermore, module preservation analysis between colorectal cancer patients with and without metastatic recurrence suggests hypotheses on the nature of the different local metabolic pathways.READ MORE
Treatment Options for Chronic Parvovirus Viremia in Pediatric Heart Transplant Patients in a Tertiary Care CenterPoster
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE